PHASE 2A STUDY OF ZW25 IN COMBINATION WITH PALBOCICLIB PLUS FULVESTRANT
- Registry ID
- ZWI-ZW25-202
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- JAZZ PHARMACEUTICALS IRELAND LIMITED
- Start date
- 2024-04-05
- Last update
- 2019-09-25
Conditions
- BREAST CANCER HER2-POSITIVE
- BREAST CANCER
Related clinical trials
- A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN-LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES
- 68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
- A PHASE IB/II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY
EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF
GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN
COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN
PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC
ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6
INHIBITOR
- A PHASE 3 OPEN-LABEL RANDOMIZED STUDY ASSESSING THE EFFICACY AND
SAFETY OF RLY-2608 + FULVESTRANT VERSUS CAPIVASERTIB + FULVESTRANT AS TREATMENT FOR
PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR
2 NEGATIVE (HR+/HER2-) LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE OR PROGRESSION ON OR AFTER TREATMENT WITH A CDK4/6 INHIBITOR
View on source registry